Maintaining credibility and integrity through independence from industry influence is a cornerstone of GINN’s mission. We are committed to fostering a transparent and independent relationship with stakeholders, especially public health professionals. To uphold this commitment, GINN does not accept funding from transnational or multinational tobacco companies. GINN welcomes smokeless tobacco companies, but those involved in…
How-To Guides Step-by-Step Instructions for Each Product Nicotine Pouches: Nicotine Strips: Nicotine Lozenges: Nicotine Gum: Heat Not Burn Systems: Dissolvable Nicotine Products: Potential Side Effects Best Practices FAQs What nicotine level should I choose? Can I use nicotine products with other medications? How long should I use nicotine alternatives? Are these products safe during pregnancy?…
Switching from smoking to alternative nicotine products can be challenging, but with the right strategies and support, it is achievable. Here’s a guide to help smokers make a successful transition. Why Transition to Alternatives? Steps for a Successful Transition Success Stories Expert Tips By embracing alternative nicotine products responsibly and with proper guidance, smokers can…
As the popularity of alternative nicotine products continues to grow, understanding their safety and legal regulations is critical for both consumers and policymakers. Proper use and adherence to safety guidelines ensure that these products serve as effective tools for harm reduction while minimizing risks. Legal Regulations The legal landscape for nicotine products varies across regions.…
Nicotine has long been at the center of debates surrounding smoking and its associated health risks. However, widespread misinformation—or disinformation, as it is often deliberately designed to confuse the public and consumers—continues to obscure the facts about nicotine’s actual role in tobacco-related diseases. By addressing these myths and focusing on evidence-based knowledge, we can improve…
1. Executive Summary Safer nicotine products (SNPs), such as nicotine pouches, lozenges, gums, dissolvables and other reduced-risk nicotine alternatives, should not be regulated in the same manner as combustible smoking tobacco products and nicotine vaping products because they– • are smokeless and do not pose the same relative health risks; • readily contribute to a…
As the global conversation on tobacco harm reduction evolves, regulatory frameworks for novel nicotine products are under scrutiny. Broughton Life Sciences Ltd., a leading consultancy in life sciences, recently submitted comprehensive recommendations to the UK Parliament, offering a roadmap for establishing safety, quality, and compliance standards for nicotine pouches and other reduced-risk alternatives. Key Recommendations…